Exploring its impact across different patient profiles, such as oncologic versus non-oncologic individuals, various types of diabetes, insulin use, or baseline CRP, could provide valuable insights into how these treatments influence muscle decline in distinct pathophysiological contexts. Here, CRP is linked to diabetes mellitus.